Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Rivus Pharmaceuticals Inc.
Headquarters: Charlottesville, VA, United States of America
Website: https://www.rivuspharma.com/...
Year Founded: 2019
Status: Private
BioCentury | Dec 17, 2024
Product Development
Obesity newcos aim for differentiation
New targets start to outnumber incretins among start-ups exploring paths to deeper, higher-quality weight loss
BioCentury | Aug 14, 2024
Product Development
Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity
Plus: Readouts from Avidity, Apellis/Sobi, Levicept and Merck
BioCentury | Mar 12, 2024
Discovery & Translation
Distillery spotlight: new mitochondrial mechanisms from academia
Correcting mitochondrial dynamics, metabolic control of pathogenic or therapeutic cells emerge among translational innovations in BioCentury’s survey of 2023 publications
BioCentury | Dec 22, 2023
Discovery & Translation
Move over oncology — I&I will write the next big stories in innovation
Biotech execs, investors eye immunology and inflammation, plus neurology as innovation drivers, but precision medicine still to prove itself: a BioCentury survey
BioCentury | Nov 15, 2023
Management Tracks
Rivus appoints Smith as chair and hires Schott as CMO
Plus: Noema and K36 hire CMOs and more from Myricx, Outlook and IMIDomics
BioCentury | Aug 10, 2023
Product Development
Obesity mechanisms in the clinic: which overlap, and which branch out
Like incretins, most clinical programs modulate glucose homeostasis and appetite, but a few work in new ways that could be more selective for fat loss
BioCentury | Jun 29, 2023
Management Tracks
Dallas replaces Cunningham as CEO of Rivus
Plus: Stephen Uden named CEO at Rallybio, and updates from Alloy, TScan and more
BioCentury | Mar 29, 2023
Product Development
Next up in obesity therapeutics
Late-stage pipeline dominated by large pharmas, GLP-1 combinations
BioCentury | Sep 22, 2022
Finance
With Rivus’ first-in-class obesity therapy in clinic, RA leads $132M series B
Virginia-based start-up has begun Phase IIa heart failure study, is planning Phase IIb trial in obesity that will include diabetic patients
BioCentury | Feb 10, 2022
Product Development
Rivus reports weight loss POC with metabolic accelerator
Mechanism leads to significant weight loss, fat reduction in Phase IIa
Items per page:
1 - 10 of 12